Curevo Vaccine

Curevo Vaccine

  • Founded: 2017
  • Location: Bothell, WA
  • Employee range: 11 - 50
  • Clinical stage: Clin2b
  • Therapy area: Shingles
  • Drug types: INF, VAC, PED
  • Lead product: CRV-101
  • Product link:
  • Funding: $26M A1 Nov 2022; $60M A Feb 2022
  • Investors: Janus Henderson Investors, RA Capital Management, Adjuvant Capital, GC Biopharma

job board

Short description:


Drug notes:

Also RD varicella in immunocompromised children

Long description:

Curevo Vaccine is reducing the burden of infectious diseases through the development of high effective vaccines. Adjuvanted sub-unit vaccines do not contain virus components and so do not cause infection, yet they produce an optimal immune response. Using a combination of expertise in immunology, protein science, adjuvant technology and regulatory operations, Curevo is creating safe and effective vaccines from the bench through to market to address global unmet clinical needs. Curevo’s first vaccine candidate, CRV-101, is an adjuvanted sub-unit vaccine for the protection from Shingles in older adults and for protection from Chickenpox in immunocompromised children. CRV-101 is currently in clinical trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy